SarCNU in Treating Patients With Recurrent or Metastatic Colorectal Cancer
A Phase II Study of Second-Line SarCNU (NSC 364432) in Patients With Recurrent/Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of sarCNU in treating patients who have recurrent or metastatic colorectal cancer.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
OBJECTIVES:
- Determine the efficacy of SarCNU in patients with recurrent or metastatic colorectal cancer.
- Determine the qualitative and quantitative toxicity of this drug in these patients.
- Determine the time to progression and survival of patients treated with this drug.
OUTLINE: This is a multicenter study.
Patients receive oral SarCNU on days 1, 5, and 9. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) receive 2 additional courses beyond documentation of CR. Patients who achieve partial response (PR) receive 4 additional courses beyond documentation of PR.
Patients are followed at 4 weeks and then every 3 months thereafter.
PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 6-8 months.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R3E 0V9
- CancerCare Manitoba
-
-
Ontario
-
Kingston、Ontario、カナダ、K7L 5P9
- Kingston Regional Cancer Centre
-
Ottawa、Ontario、カナダ、K1H 1C4
- Ottawa Regional Cancer Centre
-
Toronto、Ontario、カナダ、M5G 2C4
- Toronto General Hospital
-
Toronto、Ontario、カナダ、M5G 2M9
- Princess Margaret Hospital
-
-
Quebec
-
Montreal、Quebec、カナダ、H2W 1S6
- McGill University
-
Montreal、Quebec、カナダ、H2L 4MI
- Hopital Notre- Dame du CHUM
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
Histologically confirmed colorectal cancer
- Locally recurrent or metastatic disease
- Previously treated with 1 chemotherapy regimen for recurrent or metastatic disease
At least 1 unidimensionally measurable lesion
- At least 20 mm by conventional techniques OR
- At least 10 mm by spiral CT scan
- No prior radiotherapy to indicator lesion (clear disease progression or new lesion within a prior radiation port is acceptable)
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- Not specified
Hematopoietic:
- Absolute granulocyte count at least 1,500/mm^3
- Platelet count at least 120,000/mm^3
Hepatic:
- Bilirubin normal
- AST and ALT no greater than 2.5 times upper limit of normal
Renal:
- Creatinine normal OR
- Creatinine clearance at least 60 mL/min
Cardiovascular:
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
Pulmonary:
- DLCO at least 80% predicted
- FVC at least 80% predicted
- No history of significant pulmonary disease
- No concurrent symptomatic pulmonary disease (e.g., chronic obstructive pulmonary disorder, chronic asthma)
Other:
- No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix
- No other serious illness or medical condition that would preclude study
- No ongoing or active uncontrolled infection
- No history of significant neurologic or psychiatric disorder that would preclude study
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3 months after study
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 4 weeks since prior immunotherapy
- No concurrent immunotherapy
Chemotherapy:
- See Disease Characteristics
- Prior adjuvant chemotherapy allowed
- No prior nitrosoureas
- No prior second-line chemotherapy for recurrent or metastatic disease
- At least 4 weeks since prior chemotherapy
- No other concurrent chemotherapy
Endocrine therapy:
- No concurrent corticosteroids
Radiotherapy:
- See Disease Characteristics
- Prior radiotherapy as part of primary therapy allowed
- At least 4 weeks since prior radiotherapy
- No concurrent radiotherapy
Surgery:
- Prior surgery as part of primary therapy allowed
- Prior reoperation for recurrent disease allowed
- At least 2 weeks since prior surgery other than biopsy
Other:
- At least 4 weeks since prior investigational agent
- No other concurrent investigational agents or therapy
- No other concurrent anticancer therapy
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
協力者と研究者
捜査官
捜査官
- スタディチェア:Ralph PW Wong, MD, FRCPC、CancerCare Manitoba
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
その他の研究ID番号
- I146
- CAN-NCIC-IND146 (その他の識別子:PDQ)
- CDR0000069113 (その他の識別子:PDQ)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。